Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (143)

2024

  1. Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study

    Diabetes Research and Clinical Practice, Vol. 207

  2. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

    Atherosclerosis, Vol. 393

  3. New Perspectives for Low Muscle Mass Quantity/Quality Assessment in Probable Sarcopenic Older Adults: An Exploratory Analysis Study

    Nutrients, Vol. 16, Núm. 10

2023

  1. CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction

    Frontiers in Endocrinology, Vol. 14

  2. Impact of conducting a genetic study on the management of familial hypercholesterolemia; A retrospective cohort study of 4854 patients from the SEA Dyslipidemia Registry

    Journal of Clinical Lipidology, Vol. 17, Núm. 6, pp. 717-731

  3. Letter to the Editor: Remission of Graves’ Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis

    Thyroid

  4. Low Muscle Mass Is Associated with Poorer Glycemic Control and Higher Oxidative Stress in Older Patients with Type 2 Diabetes

    Nutrients, Vol. 15, Núm. 14

  5. Metabolomic signature and molecular profile of normal and degenerated human intervertebral disc cells

    Spine Journal, Vol. 23, Núm. 10, pp. 1549-1562

  6. Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes

    Diabetes Therapy, Vol. 14, Núm. 4, pp. 723-736

2022

  1. A Very Rare Variant in SREBF2, a Possible Cause of Hypercholesterolemia and Increased Glycemic Levels

    Biomedicines, Vol. 10, Núm. 5

  2. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?

    Biology, Vol. 11, Núm. 8

  3. Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity

    Microvascular Research, Vol. 139

  4. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players

    Biomedicine and Pharmacotherapy, Vol. 145

  5. Corticotroph cell hyperplasia as a rare cause of ACTH-dependent Cushing syndrome

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 9, pp. 694-701

  6. DECREASED URINARY LEVELS OF SIRT1 AS NON-INVASIVE BIOMARKER OF EARLY RENAL DAMAGE IN HYPERTENSION

    Journal of hypertension, Vol. 40, pp. e249

  7. Developing a simple and practical decision model to predict the risk of incident type 2 diabetes among the general population: The Di@bet.es Study

    European Journal of Internal Medicine, Vol. 102, pp. 80-87

  8. Effect of personality on blood glucose control in patients with type 1 diabetes

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 9, pp. 677-685

  9. First clinical and efficacy data on evolocumab in routine clinical practice in endocrinology and nutrition services in Spain: a retrospective observational study (RETOSS-ENDO)

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 7, pp. 540-542

  10. Immune-mediated necrotising inflammatory myopathy. A rare side effect of statins

    Endocrinologia, Diabetes y Nutricion, Vol. 69, Núm. 8, pp. 648-649

  11. Impact of COVID-19 lockdown on diabetes management and follow-up in a broad population in Spain

    European Journal of Clinical Investigation, Vol. 52, Núm. 6